Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different Manufacturers
A Study to Evaluate the Immunogenicity and Safety of Sequential Vaccination Among Infants With Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains (Hereinafter as "sIPV") From Different Manufacturers.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Lei Wang
- Phone Number: 18986142864
- Email: 372491281@qq.com
Study Contact Backup
- Name: Weijun Chen
- Phone Number: 13995866167
- Email: 446109793@qq.com
Study Locations
-
-
-
Xiaogan, China
- Disease Control and Prevention Center, Xiaonan District, Xiaogan City
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- (1) Healthy infants of ≤ 12 months of age;
- (2) Can provide proof of legal identity;
- (3) Have completed two doses of sIPV vaccination at Beijing Institute;
- (4) Able to provide proof of sIPV vaccination;
- (5) The participant's guardian can understand and agree to sign the informed consent form.
Exclusion Criteria:
- (1) Known severe allergy to vaccines or vaccine components, such as urticaria, dyspnea, angioneurotic edema;
- (2) Received immunoglobulins or other blood products, or plan to receive such treatment during the study;
- (3) Received ≥14 days of immunosuppressive or other immunomodulatory therapy or cytotoxic therapy, or plan to receive such therapy during the study;
- (4) Received another investigational vaccine within 28 days before receiving the study vaccine;
- (5) Received a live attenuated vaccine within 14 days before receiving the trial vaccine;
- (6) Received a subunit or inactivated vaccine within 7 days before receiving the trial vaccine;
- (7) Acute exacerbation of various acute illnesses or chronic diseases within the last 7 days;
- (8) Those who had a fever with an axillary temperature >37.0°C before receiving the study vaccine;
- (9) Participants who, in the judgment of the investigator, have any other factors that make them unsuitable for participation in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: experimental group
sIPV: Sinovac Biotech Co., Ltd., Beijing
|
One dose of the experimental/control vaccine will be administered to 4-month-old infants who have already received two doses of sIPV from Beijing Institute of Biological Products Co., LTD.
|
|
Active Comparator: control group
sIPV: Beijing Institute of Biological Products Co., LTD.
|
One dose of the experimental/control vaccine will be administered to 4-month-old infants who have already received two doses of sIPV from Beijing Institute of Biological Products Co., LTD.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Geometric Mean Increase (GMI)
Time Frame: 30 days
|
-The neutralizing antibody GMI against different types (Type I, II and III) at day 30 after vaccination;
|
30 days
|
|
Geometric Mean Titer (GMT)
Time Frame: 30 days
|
-The neutralizing antibody GMT against different types (Type I, II and III) at day 30 after vaccination;
|
30 days
|
|
Seropositivity rate
Time Frame: 30 days
|
-The seropositivity rate of neutralizing antibody against different types (Type I, II and III) at day 30 after vaccination;
|
30 days
|
|
Seroconversion rate
Time Frame: 30 days
|
-The seroconversion rate of neutralizing antibody against different types (Type I, II and III) at day 30 after vaccination;
|
30 days
|
|
Adverse reaction incidence
Time Frame: 30 days
|
-The incidence of adverse reaction within 30 days after vaccination;
|
30 days
|
|
Serious adverse events incidence
Time Frame: 30 days
|
-The incidence of serious adverse events within 30 days after vaccination.
|
30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Lei Wang, Hubei Provincial Center for Disease Control and Prevention
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PRO-sIPV-4002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.